-
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
NCT03394365 ·
Phase: Phase 3 ·
Ages: No age limits stated ·
Sex: All (male and female)
· Tennessee: Memphis, Nashville
-
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
NCT05489705 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
NCT06979362 ·
Phase: Phase 2 ·
Ages: 40 Years to 84 Years ·
Sex: All (male and female)
· Tennessee: Nashville
-
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Greeneville, Jackson
-
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
NCT06056297 ·
Phase: Phase 3 ·
Ages: 12 Years and older ·
Sex: All (male and female)
· Tennessee: Memphis
-
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
NCT06024746 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Chattanooga
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
NCT06008197 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Germantown, Memphis, Nashville
-
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Jackson, Jefferson City
-
AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM
NCT06378632 ·
Phase: Not specified ·
Ages: 22 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
ANDREAS Registry (Assessment of Novel Drug-coated Balloon Revascularization: Effectiveness, Angiographic Outcomes, and Safety)
NCT07559903 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
Alleviant ALLAY-HF Study
NCT05685303 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 40 Years and older ·
Sex: All (male and female)
· Tennessee: Germantown, Knoxville
-
Alleviant ALLAY-HFrEF Study
NCT06812533 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Knoxville
-
Assessment of CCM in HF With Higher Ejection Fraction
NCT05064709 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Germantown
-
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
NCT07232030 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Chattanooga
-
CCM OPEN HF Registry
NCT07112924 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Germantown
-
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
NCT05485961 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Chattanooga, Knoxville, Memphis, Nashville
-
ELEVATE-HFpEF Clinical Study
NCT06678841 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 40 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
NCT05714085 ·
Phase: Phase 2, Phase 3 ·
Ages: 29 Days to 17 Years ·
Sex: All (male and female)
· Tennessee: Memphis
-
Exercise Testing After Preeclampsia
NCT06741436 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: Female
· Tennessee: Nashville
-
Familial Investigations of Childhood Cancer Predisposition
NCT03050268 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Tennessee: Memphis
-
Home-Based Cardiac Rehabilitation for Patients With Heart Failure
NCT06479876 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
NCT06310031 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 100 Years ·
Sex: All (male and female)
· Tennessee: Memphis
-
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398 ·
Phase: Phase 3 ·
Ages: 18 Years to 85 Years ·
Sex: All (male and female)
· Tennessee: Nashville
-
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459 ·
Phase: Phase 3 ·
Ages: 18 Years to 99 Years ·
Sex: All (male and female)
· Tennessee: Jackson, Oak Ridge, Powell, Tullahoma
-
OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels
NCT06939751 ·
Phase: Not specified ·
Ages: 18 Years to 99 Years ·
Sex: All (male and female)
· Tennessee: Nashville
-
Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs
NCT06532890 ·
Phase: Not specified ·
Ages: Up to 18 Years ·
Sex: All (male and female)
· Tennessee: Nashville
-
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
NCT05934487 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
NCT04278404 ·
Phase: Not specified ·
Ages: 0 Years to 20 Years ·
Sex: All (male and female)
· Tennessee: Nashville
-
Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence
NCT06374277 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Knoxville, Memphis
-
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060 ·
Phase: Phase 3 ·
Ages: 40 Years and older ·
Sex: All (male and female)
· Tennessee: Cleveland, Morristown, Nashville
-
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
NCT00271180 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Tennessee: Germantown, Nashville
-
REHAB Fontan Failure: A Trial of Cardiac Rehabilitation
NCT06150950 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
NCT06777368 ·
Phase: Not specified ·
Ages: 18 Years to 105 Years ·
Sex: All (male and female)
· Tennessee: Nashville
-
Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM
NCT07690436 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Germantown
-
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
NCT07069738 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville
-
Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy
NCT07172971 ·
Phase: Phase 1 ·
Ages: 8 Years to 18 Years ·
Sex: Male
· Tennessee: Nashville
-
Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction
NCT02901184 ·
Phase: Phase 3 ·
Ages: 50 Years to 99 Years ·
Sex: All (male and female)
· Tennessee: Germantown
-
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574 ·
Phase: Phase 3 ·
Ages: 18 Years to 85 Years ·
Sex: All (male and female)
· Tennessee: Germantown, Knoxville, Nashville, Tullahoma
-
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652 ·
Phase: Phase 3 ·
Ages: 18 Years to 130 Years ·
Sex: All (male and female)
· Tennessee: Jackson, Knoxville, Memphis, Nashville
-
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
NCT03142152 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Memphis, Nashville
-
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
NCT06526195 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Memphis
-
Wearable Technology to Evaluate Hyperglycemia and HRV in DMD
NCT06124196 ·
Phase: Not specified ·
Ages: 10 Years and older ·
Sex: Male
· Tennessee: Nashville
-
Wearable Technology to Evaluate Hyperglycemia and HRV in DMD - Longitudinal Aim
NCT06093100 ·
Phase: Not specified ·
Ages: 10 Years and older ·
Sex: Male
· Tennessee: Nashville
-
XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)
NCT06895070 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Tennessee: Nashville